This activity is supported by an unrestricted educational grant from Gilead Sciences, Inc.
Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
Deborah M. Stephens, DO
Huntsman Cancer Institute
Amy L. Goodrich, MSN, CRNP
Johns Hopkins University
New treatment options and shifting paradigms in the approach and management of CLL patients, present care challenges, especially with newer oral agents. This activity discusses risk-stratification, targeting pathways and best practices to improve patient outcomes: how/when to incorporate old therapies vs. newer treatments and the management of patients with CLL in this rapidly changing treatment landscape.
These CME/CE/CPE accredited activities are jointly provided by